Insilico Medicine executives will share insights on leveraging generative AI in drug discovery and healthcare delivery at Dubai AI Festival 2026 and the 2026 Global Healthcare Innovation Summit in Hong Kong. In Seoul, Dr. Jue Wang will deliver a keynote on maximizing AI's value in AI drug discovery at BioPlus-Interphex Korea 2026.
inClinico Agent automates and optimizes clinical trial intelligence, predicting trial outcomes with high accuracy. The platform achieves an overall AUROC of 0.805 and an accuracy of 0.734, with Phase 3 trial accuracy reaching 0.780.
Insilico Medicine is presenting first-in-human data for AI-designed cancer drug ISM6331, a pan-TEAD inhibitor targeting the Hippo/TEAD pathway in mesothelioma and other advanced solid tumors. The study's results will be discussed at the ESMO Congress 2026.
Insilico Medicine has achieved the early drug discovery milestone in its multi-year AI-driven drug discovery collaboration with Servier, triggering an undisclosed milestone payment. The milestone triggers an undisclosed payment from Servier to Insilico, following the successful fulfillment of predefined program criteria.
Insilico Medicine will exhibit its AI-driven drug discovery and anti-aging science at the Abu Dhabi Future Health Summit and the Regenerative Medicine Congress 2026. The company's CEO will participate in panel discussions and deliver a keynote speech on the future of drug discovery and generative AI.
Pharma.AI's MMAI Gym enables scientists to adapt AI models to specific tasks, achieving performance matching or exceeding the state of the art across 70 chemistry and biology benchmark tasks. The company also introduced Generative Biologics, Chemistry42, and PandaOmics, providing tools for designing and predicting properties of molecul...
Insilico Medicine has nominated ISM9546, an orally bioavailable VAV1 degrader, as a potential treatment for autoimmune diseases. The compound has shown sub-nanomolar VAV1 degradation potency and robust efficacy in preclinical studies.
Researchers are developing new approaches to model interconnected biological processes, identify opportunities for intervention, and translate insights into measurable improvements in human health. Longevity therapeutics face an actionable regulatory framework to ensure clinical validation and market access.
Insilico Medicine nominates ISM1354, a novel small molecule GIPR antagonist, with robust weight-loss efficacy and improved pharmacokinetic and safety profiles. ISM1354 demonstrates a favorable safety profile, with minimal effects on cell viability and a lower potential hepatotoxicity risk.
Insilico Medicine will present its latest advances in LLM-driven drug discovery, autonomous robotics labs, and interdisciplinary scientific breakthroughs at AI Everything Abu Dhabi and BioJapan 2026. The company's leaders will also share insights into AI biology of aging, anti-aging interventions, and longevity drug discovery at the Ab...
The Pharma.AI 2026 Q3 Fall Update showcases the rise of agentic AI in pharmaceutical intelligence, automating discovery workflows with autonomous agents. Insilico Medicine's platforms, including Generative Biologics, PandaOmics, and Chemistry42, demonstrate the power of agentic AI in accelerating drug discovery and development.
Insilico Medicine will present initial Phase I data for ISM6331, a pan-TEAD inhibitor, in patients with advanced solid tumors and mesothelioma. The treatment targets the Hippo pathway, a key regulator of cell growth and survival.
ARDD 2026 brings together global pharmaceutical executives, biotechnology leaders, regulators, investors and researchers to discuss aging biology, clinical development, artificial intelligence and pharmaceutical R&D. The conference features senior leaders from top pharma companies, FDA representatives and XPRIZE Healthspan finalists.
Inailico Medicine has developed an open AI toolkit, including LongevityBench, Longevity-LLMs, and LongevityClaw, to accelerate research and therapeutic development in aging and longevity. The toolkit aims to help scientists identify and develop the next generation of longevity interventions.
Insilico Medicine has discovered novel BTK degraders using its proprietary generative AI platform, Chemistry42, with potent degradation and encouraging preclinical properties. The lead compounds, ISM-PR25 and ISM-PR44, achieved picomolar BTK degradation activity and oral bioavailability in mice.
Insilico Medicine's AI-driven drug candidate, rentosertib, achieved a unanimous reversal of biological age across six independent proteomic aging clocks in a Phase IIa clinical trial. The study demonstrated significant reductions in predicted biological age and reversals of up to six years, with key biological mechanisms involving seno...
Insilico Medicine's Longevity Vaccines initiative uses generative AI and programmable RNA medicine to eliminate early cellular drivers of age-related diseases. The approach targets senescent, fibrotic, and autoreactive cells, starting with immune system rejuvenation.
Insilico Medicine executive team to speak at premier healthcare and AI Summits in New York, Riyadh, and Shanghai, showcasing latest breakthroughs in generative AI-driven drug discovery and anti-aging interventions.
Insilico Medicine has dosed the first patient in the GENESIS-IPF-3 Phase III clinical trial of Rentosertib, a generative AI-driven innovative drug for idiopathic pulmonary fibrosis. The 52-week trial aims to evaluate Rentosertib's efficacy and safety in a larger cohort of patients with IPF.
Researchers evaluated biological age using six internationally recognized proteomic aging clocks, finding a reduction in predicted biological age among patients treated with rentosertib. The drug also showed promising dose-dependent reversal of Forced Vital Capacity (FVC), a measure of lung function declining with age.
Insilico Medicine's inclusion in the HKEX Tech 100 Index underscores its advancements in AI-driven drug discovery and healthcare. The company has reported significant revenue growth and achieved its first profitable half-year, with its AI technology capabilities driving expansion and liquidity.
Insilico Medicine has released state-of-the-art (SOTA) MMAI specialist models for chemistry and biology, achieving superior performance on over 70 benchmark tasks. These models demonstrate the potential of language models to compete with dedicated scientific methods in drug discovery.
Insilico Medicine leaders will share AI-driven insights at key tech events, including LEAP 2026 and the UBS China A-Share Conference. The company will discuss how AI drug discovery is reshaping R&D paradigms, enhancing efficiency and innovation value.
Insilico Medicine convenes O3DC, an open initiative addressing critical limitations in benchmarks for AI-driven drug discovery. The consortium catalogues hundreds of benchmarks across 10 categories, including molecular property prediction and binding affinity.
Dr. Alex Aliper will share insights on how cutting-edge technological innovation can drive industrial growth at the Global Unicorn Summit, and discuss AI applications in precision medicine at MedTech World Asia. He will also present real-world case studies and explore industry challenges in applying AI to personalized healthcare.
ARDD 2026 will convene leaders from pharma, biotechnology, academia, clinical medicine, investment, AI and policy to present research and exchange perspectives on longevity biotechnology. The meeting will address therapeutic development and commercialization, with sessions on clinical trials, regulatory pathways, and AI in healthspan.
Insilico Medicine has been nominated for the 2026 Prix Galien USA 'Best Start-Up' Award for its generative AI-driven approach in biotechnology. The nomination follows significant advancements in its lead AI-discovered drug, rentosertib, and its expansion of collaborations with pharmaceutical companies.
Insilico Medicine's inclusion in the MSCI Global Small Cap Indexes reflects growing recognition of its core strengths in AI-powered drug discovery. The Company is expected to benefit from increased international visibility, passive capital inflows, and improved trading liquidity.
Insilico Medicine introduces the Virtual Aging Cell (VAC) platform, which leverages multi-agent AI to simulate cellular processes, including differentiation, reprogramming, and aging. The VAC platform aims to support target identification, cellular fate intervention, novel drug discovery, and geroscience research.
Insilico Medicine has nominated ISM0900, a potent and selective oral Lp(a) inhibitor, as a preclinical candidate for managing cardiovascular risks. The compound demonstrates rapid onset, excellent oral pharmacokinetics, and superior efficacy in reducing Lp(a) levels.
Researchers identified NDRG1 as a key regulator of DNA damage repair, which can be targeted by the antimalarial drug quinacrine to trigger synthetic lethality in specific cancer subtypes. The study also reveals potential strategies for targeting DNA damage response based on NDRG1 expression.
ISM9077 boasts potent inhibition across species, excellent exposure and permeability traits, and a favorable safety profile in preclinical studies. It modulates pathological inflammation, supporting broad indication expansion into therapeutic areas like aging and neurodegenerative diseases.
A collaborative study between Insilico Medicine and top research institutions uses AI to identify therapeutic targets for IP-SNSCC, a rare and aggressive subset of head and neck cancers. The study provides the first comprehensive molecular atlas of this disease, enabling future translational research.
ISM8969/HT-001 is an orally available, brain-penetrant NLRP3 inhibitor with promising in vitro and in vivo profiles. The clinical trial aims to evaluate its safety, tolerability, and efficacy in patients with Parkinson's disease.
Insilico Medicine's Dr. Alex Zhavoronkov will deliver two keynotes on AI-driven drug discovery and anti-aging at Ai4 2026. The panel discussion explores the evolution of AI in medicine, while the solo keynote delves into the company's strategy for breakthrough innovation using frontier AI models.
The DDD Benchmark provides an independent, real-world measure of how a model performs in drug discovery. It comprises two evaluation suites: Drug Discovery Foundations and Drug Candidate Essentials.
ISM6331, a novel pan-TEAD inhibitor, has received Fast Track Designation from the FDA for treating adult patients with unresectable malignant pleural mesothelioma. The treatment boasts synergistic anti-tumor effects and potential to overcome drug resistance as combination therapy.
Insilico Medicine presents first-in-human Phase 1 study data for its novel AI-designed pan-TEAD inhibitor ISM6331, targeting complex oncogenic drivers like the Hippo pathway. The study assesses safety, pharmacokinetics, and preliminary antitumor activity in patients with advanced mesothelioma and other solid tumors.
The US and China have distinct advantages in different domains, with the US lacking efficient translational infrastructure and China building a more efficient biomedical development engine. The conversation will address areas of collaboration and competition in biopharmaceutical innovation.
Insilico Medicine has nominated an AI-driven novel compound ISM9528 for pain management, addressing the $100 billion market challenge. The compound targets Target Z and offers a non-opioid treatment approach with superior efficacy and safety profile.
At CPIC 2026, Insilico Medicine's Dr. Alex Zhavoronkov and Dr. Feng Ren presented on their approach to AI-driven life sciences, leveraging the Pharma.AI platform for agile translation and closed-loop validation. The duo emphasized the importance of technological breakthroughs and clinical validation in shaping the future of R&D.
The strategic alliance combines Insilico's Pharma.AI platform with Bora's global capabilities to explore a next-generation drug innovation model. The partnership aims to accelerate Bora's transition towards AI-driven drug discovery and development, leveraging Insilico's comprehensive research and development strategies.
The collaboration aims to advance co-development of R&D programs by combining Insilico's validated AI platform with CMS's therapeutic expertise. The partnership enables the development of innovative drugs for central nervous system conditions, streamlining the process and accelerating delivery of clinically meaningful innovations.
The 13th Aging Research & Drug Discovery (ARDD) Meeting will take place from October 1-3, 2026, at the David Rubenstein Treehouse at Harvard University. The conference features a comprehensive program with daily tracks focused on clinical translation and industry growth.
Insilico Medicine will deliver a keynote speech and participate in a panel discussion on the future of drug discovery with generative AI. The company showcases its innovative approach to accelerating drug development, compressing timelines and enabling sustainable growth.
Insilico Medicine achieved a significant revenue increase of 272.7% to 287.3% for the First Half of 2026, with net profit expected in the range of USD33.5 million to USD39.5 million. Global collaborations and strategic partnerships drove business growth, with major deals secured with top pharmaceutical companies.
Rentosertib is a potentially first-in-class oral small-molecule inhibitor targeting TNIK for the treatment of idiopathic pulmonary fibrosis. The Phase III clinical trial will evaluate the efficacy and safety of once-daily Rentosertib administered over 52 weeks.
Insilico Medicine has expanded its generative AI capabilities through a strategic collaboration with Liquid AI, yielding models optimized for retrosynthesis and multi-omics target discovery. The company's platform upgrades enable enterprise-grade automation, parallel simulation, and precision sifting in biologics design.
Insilico Medicine is leveraging its end-to-end Pharma.AI platform to drive clinical validation in AI drug discovery, with a diversified pipeline featuring over 40 projects. The company has nominated 31 development candidates and achieved positive results in a Phase IIa clinical trial for Rentosertib, an AI-discovered TNIK inhibitor for...
The collaboration aims to identify clinically differentiated drug candidates using Insilico's generative AI and Takeda's global development capabilities. The partnership seeks to deliver meaningful treatment options for patients and support Takeda's transition to an AI-native discovery model.